Details of the Drug Combinations

General Information of This Drug (ID: DM4ONW5)

Drug Name

Baricitinib DM4ONW5

Synonyms

Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Baricitinib + Methotrexate	DC23FEJ	Methotrexate	Arthritis, Rheumatoid	[3]
Baricitinib + Prednisolone	DCIVXS6	Prednisolone	IgG4-related Disease With Eosinophilia	[4]
Baricitinib + Danazol	DC7K03A	Danazol	Immune Thrombocytopenia	[5]
Baricitinib + Triamcinolone	DCCGGQR	Triamcinolone	Atopic Dermatitis	[6]
Baricitinib + Hydroxychloroquine	DCNWGOT	Hydroxychloroquine	Symptomatic COVID-19 Infection Laboratory-Confirmed	[7]
Dexamethasone + Baricitinib	DCFEIUW	Dexamethasone	Immune Thrombocytopenia	[8]
Dexamethasone + Baricitinib	DC8G8SV	Dexamethasone	Covid19	[9]
Remdesivir + Baricitinib	DC7UJ5S	Remdesivir	COVID-19	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DrugCom(s)

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT01185353) A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
4	ClinicalTrials.gov (NCT05781516) Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
5	ClinicalTrials.gov (NCT05852847) Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
6	ClinicalTrials.gov (NCT02576938) A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
7	ClinicalTrials.gov (NCT04373044) Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
8	ClinicalTrials.gov (NCT05932524) Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
9	ClinicalTrials.gov (NCT04832880) Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
10	ClinicalTrials.gov (NCT04401579) Adaptive COVID-19 Treatment Trial 2 (ACTT-2)